176 related articles for article (PubMed ID: 23977537)
21. Diffuse malignant pleural mesothelioma in an urban hospital: clinical spectrum and trend in incidence over time.
Shepherd KE; Oliver LC; Kazemi H
Am J Ind Med; 1989; 16(4):373-83. PubMed ID: 2610210
[TBL] [Abstract][Full Text] [Related]
22. How I treat malignant pleural mesothelioma.
Viscardi G; Di Liello R; Morgillo F
ESMO Open; 2020 Mar; 4(Suppl 2):e000669. PubMed ID: 32156681
[TBL] [Abstract][Full Text] [Related]
23. Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.
Augeri S; Capano S; Morone S; Fissolo G; Giacomino A; Peola S; Drace Z; Rapa I; Novello S; Volante M; Righi L; Ferrero E; Ortolan E; Funaro A
Oncotarget; 2018 Apr; 9(32):22785-22801. PubMed ID: 29854315
[TBL] [Abstract][Full Text] [Related]
24. Solitary cerebellar metastasis of malignant pleural mesothelioma: case report.
Winfree CJ; Mack WJ; Sisti MB
Surg Neurol; 2004 Feb; 61(2):174-8; discussion 178-9. PubMed ID: 14751636
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of DDX39 in human malignant pleural mesothelioma cell lines compared to normal pleural mesothelial cells.
Kuramitsu Y; Tominaga W; Baron B; Tokuda K; Wang Y; Kitagawa T; Nakamura K
Anticancer Res; 2013 Jun; 33(6):2557-60. PubMed ID: 23749908
[TBL] [Abstract][Full Text] [Related]
26. The role of cytological evaluation of pleural fluid in diagnosing malignant mesothelioma.
Lovrenski A; Panjković M; Tegeltija D; Latinović LT; Krcedinac J
Med Pregl; 2012; 65(1-2):5-8. PubMed ID: 22452231
[TBL] [Abstract][Full Text] [Related]
27. [Computed tomography findings of malignant pleural mesothelioma].
Shiota Y; Sato T; Yamaguchi K; Ono T; Kaji M; Niiya H
Nihon Kyobu Shikkan Gakkai Zasshi; 1994 Apr; 32(4):309-14. PubMed ID: 8041037
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
Tian L; Zeng R; Wang X; Shen C; Lai Y; Wang M; Che G
Oncotarget; 2017 Jul; 8(28):46425-46435. PubMed ID: 28507279
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].
Tokuyama T; Yoneda T; Hamada K; Yoshikawa M; Fu A; Tomoda K; Nakaya M; Narita N; Tamura M; Kitamura K
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jan; 33(1):39-43. PubMed ID: 7699966
[TBL] [Abstract][Full Text] [Related]
30. [The computed tomographic diagnosis of malignant pleural mesothelioma. A multicenter study].
Falaschi F; Boraschi P; Musante F; Volpini F; D'Alessandro F; Torri T; Barbieri L
Radiol Med; 1992; 84(1-2):43-7. PubMed ID: 1509143
[TBL] [Abstract][Full Text] [Related]
31. Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.
Dubois F; Bazille C; Levallet J; Maille E; Brosseau S; Madelaine J; Bergot E; Zalcman G; Levallet G
Target Oncol; 2022 Jul; 17(4):407-431. PubMed ID: 35906513
[TBL] [Abstract][Full Text] [Related]
32. [Molecular heterogeneity of malignant pleural mesotheliomas].
Tranchant R; Montagne F; Jaurand MC; Jean D
Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion.
Ak G; Tomaszek SC; Kosari F; Metintas M; Jett JR; Metintas S; Yildirim H; Dundar E; Dong J; Aubry MC; Wigle DA; Thomas CF
Biomed Res Int; 2015; 2015():635748. PubMed ID: 25756049
[TBL] [Abstract][Full Text] [Related]
34. Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma.
Watzka SB; Posch F; Pass HI; Huflejt M; Bernhard D; Hannigan GE; Müller MR
J Thorac Cardiovasc Surg; 2011 Aug; 142(2):384-9. PubMed ID: 21620418
[TBL] [Abstract][Full Text] [Related]
35. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium.
Sato A; Torii I; Okamura Y; Yamamoto T; Nishigami T; Kataoka TR; Song M; Hasegawa S; Nakano T; Kamei T; Tsujimura T
Mod Pathol; 2010 Nov; 23(11):1458-66. PubMed ID: 20657552
[TBL] [Abstract][Full Text] [Related]
36. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
37. Radiotherapy for malignant pleural mesothelioma.
Chapman E; Berenstein EG; Diéguez M; Ortiz Z
Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD003880. PubMed ID: 16856023
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
[TBL] [Abstract][Full Text] [Related]
39. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
[TBL] [Abstract][Full Text] [Related]
40. Malignant and non-malignant asbestos-related pleural and lung disease: 10-year follow-up study.
Cvitanović S; Znaor L; Konsa T; Ivancević Z; Perić I; Erceg M; Vujović M; Vuković J; Beg-Zec Z
Croat Med J; 2003 Oct; 44(5):618-25. PubMed ID: 14515425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
